Why this poison is interesting

The death cap is the botanical band's paracetamol: a poison whose entire danger is stored in a latent phase. Amanita phalloides accounts for the great majority of fatal mushroom poisonings worldwide, and it does so not because the toxin is unusually potent at the cellular level but because the poisoning hides.¹ The patient eats a good-looking meal, feels nothing for the better part of a day, develops what looks like gastroenteritis, then apparently recovers — and only on the third day, when the liver fails, does the diagnosis become obvious and the window for the one useful intervention has closed.

That structure makes amatoxin the library's clearest argument for treating on suspicion rather than on confirmation. Everything that helps — decontamination, interrupting the enterohepatic recirculation, and above all blocking further hepatocyte uptake with silibinin — works on toxin that has not yet entered the cell. Once the amatoxin is inside the hepatocyte and RNA polymerase II is shut down, there is no antidote that reaches it. The parallel with paracetamol is exact: the nomogram and the antidote both exist because the poison gives you a head start if you are willing to act before the patient looks ill.

The toxic principle

The amatoxins are bicyclic octapeptides — at least nine related compounds, of which α-amanitin is the principal toxin, with β-amanitin contributing.¹ Their target is elegant and lethal: they bind and inhibit RNA polymerase II, the enzyme that transcribes DNA into messenger RNA.

The toxin reaches the hepatocyte because it is taken up from portal blood by hepatocyte membrane transporters — the same route that makes the liver both the first and the worst-affected organ, and the route silibinin is designed to block. Amatoxins are not significantly protein-bound and are cleared from plasma within about 48 hours of ingestion, so the plasma is a transient place to find them and a poor place to remove them from.¹

Toxicokinetics

Amatoxin — a poison that has left the blood before the liver fails
Parameter	Therapeutic	In overdose	Why it changes
Absorption	Rapidly absorbed from the gut; the toxins are heat-stable and survive cooking, drying and freezing¹	No preparation detoxifies the mushroom; a cooked meal is as dangerous as a raw one	This is why 'we cooked them thoroughly' offers no reassurance, and why a shared meal means every diner is potentially exposed.
Protein binding	Not significantly protein-bound¹	Unchanged	Low binding would ordinarily favour extracorporeal removal — but the toxin has largely left the plasma by the time poisoning is recognised, which defeats that advantage.
Distribution and uptake	Taken up into hepatocytes by membrane transporters from portal blood; concentrated in the liver	Unchanged — and this uptake is the therapeutic target	Silibinin works by competing for this uptake. Its entire rationale depends on toxin still being in the circulation and not yet inside the cell — which is why early administration is everything. Established
Enterohepatic recirculation	Amatoxin excreted in bile is reabsorbed from the gut, re-presenting to the liver¹	Unchanged; this loop prolongs hepatic exposure	The enterohepatic loop is the rationale for interrupting reabsorption (activated charcoal, and historically biliary drainage), and part of what silibinin is thought to interrupt as well. Inferred
Elimination	Renal excretion of unchanged toxin; cleared from plasma within ~48 h; α-amanitin can be detected in urine¹	Renal excretion continues while renal function persists	A urinary amatoxin assay can confirm exposure but is not routinely and rapidly available, and a serum level is not a management tool.¹
Dialysability	—	No established outcome benefit. Low protein binding is outweighed by early plasma clearance and hepatic sequestration	Extracorporeal measures have been tried; the data do not document a benefit, and by the time poisoning is recognised the plasma toxin is largely gone.¹

Metabolism and the metabolites

Amatoxin is unusual in this library for having no toxic metabolite and no bioactivation — the octapeptide that is eaten is the octapeptide that inhibits RNA polymerase II. Unlike paracetamol, whose latent phase exists because NAPQI has to be made, amatoxin's latent phase exists because its damage is cumulative and downstream: transcription stops immediately, but cell death waits until protein reserves are exhausted. The gap between tracks in the timeline is therefore not a metabolic delay but a depletion delay.

Amatoxin — no activation, a slow-motion cell death, and a recirculating pool

α-amanitin (ingested mushroom)Already the toxic species. Heat-stable octapeptide; not protein-bound¹
Hepatocyte membrane uptake from portal bloodThe step silibinin competes for — blockable only before uptake
Inhibition of RNA polymerase IImRNA synthesis halts → protein production fails
Protein reserves exhausted (hours to days)Hepatocyte and renal tubular cell deathThe delay that is the latent phase — death when reserves run out, not when transcription stops
Biliary excretion then gut reabsorptionEnterohepatic recirculationRe-presents toxin to the liver — the rationale for interrupting reabsorption¹

Elimination and accumulation

The elimination story contains the whole tragedy of the poisoning. Amatoxin is cleared from the plasma within about 48 hours and excreted renally, so in one sense the body rids itself of the toxin quickly.¹ But the damage does not track the plasma level: by the time the toxin has gone, hepatocytes across the liver have had their transcription silenced for a day or more and are dying on a delay. The poison leaves before the injury peaks. This is why a falling or undetectable amatoxin level is meaningless for prognosis, why the liver function tests lag the exposure by days, and why treatment aimed at the toxin must be given while the toxin is still present — which is to say, before there is any clinical reason to think the patient is seriously ill.

Target organs — and why those

Amatoxin injures the cells that most depend on continuous protein turnover, in the order in which the toxin reaches them and in which their reserves run out.

Liver — the hepatocyte

TargetRNA polymerase II in hepatocytes, reached first via portal uptake

Why hereThe hepatocyte receives the highest toxin load — it sits directly downstream of gut absorption and actively takes amatoxin up — and it has a very high protein turnover, so it exhausts its reserves early. The combination makes the liver both the first and the worst affected organ, and centrilobular necrosis is the pathological hallmark. Established

At the bedsideTransaminases begin to rise around 36–48 h, followed by jaundice, coagulopathy, hypoglycaemia and hepatic encephalopathy in severe cases progressing to acute liver failure.¹

Kidney — the tubular epithelium

TargetRNA polymerase II in renal tubular cells; renal excretion concentrates the toxin

Why hereThe tubular cell handles excreted amatoxin and is itself a high-turnover epithelium, so it is the second organ to fail. Renal injury compounds the hepatic failure into a hepatorenal picture and removes the main route of toxin clearance. Established

At the bedsideAcute kidney injury appears in the later phase, worsening the metabolic derangement and the prognosis.

Gastrointestinal epithelium

TargetRNA polymerase II in enterocytes

Why hereThe gut lining is a rapidly renewing epithelium and is directly exposed to ingested toxin, which is why the first visible phase is a severe gastroenteritis — but a delayed one, after the latent period, distinguishing it from the early upset of benign mushrooms. Established

At the bedsideProfuse, sometimes bloody, vomiting and secretory diarrhoea in the gastrointestinal phase, severe enough to cause dehydration, electrolyte disturbance and hypotension.¹

Timeline of effects

Amatoxin — four phases, and the trap is the third

Time

What you seeWhat is happening

0 – 6–40 hLatent phase
What you seeNothing at all. No symptoms; the patient feels entirely well. Average latency about 10 h.
What is happeningAmatoxin absorbed and taken up by hepatocytes; RNA polymerase II inhibited, but cells still running on existing protein. The absence of symptoms is the poison working undetected.¹
~6–24 h onwardGastrointestinal phase
What you seeSudden severe nausea, vomiting, crampy pain and profuse, sometimes bloody, secretory diarrhoea; dehydration, electrolyte loss, hypotension.
What is happeningEnterocyte protein reserves exhausting; the delayed onset (versus 1–2 h for benign mushrooms) is the diagnostic signature. Liver and renal tests are still usually normal here.¹
36–48 hApparent convalescence
What you seeThe trap. Gastrointestinal symptoms settle and the patient seems to improve — and is sometimes discharged as 'gastroenteritis'.
What is happeningSuperficial recovery masks the real event: transaminases are beginning to climb as hepatocytes die on their delay. The improvement is of the gut symptoms, not of the poisoning.¹
Day 3–5+Hepatic (and renal) failure
What you seeRising transaminases, jaundice, coagulopathy, hypoglycaemia, encephalopathy; acute kidney injury; multiorgan failure in fatal cases.
What is happeningWidespread hepatocyte necrosis now manifest; the toxin is long gone from plasma but its downstream injury peaks. Transplantation is the only rescue once fulminant failure is established.¹

What the mechanism predicts at the bedside

Delayed gastrointestinal onset is the diagnosis until proven otherwise. Symptoms starting more than six hours after a wild-mushroom meal should be treated as possible amatoxin, and NPIS contacted, even in a patient who looks well.¹
Treat on suspicion, not on liver failure. Every toxin-directed measure works on amatoxin that has not yet entered the hepatocyte; once RNA polymerase II is inhibited there is no antidote that reaches it. Waiting for abnormal liver tests wastes the only window that matters.
Apparent recovery on day two is not recovery. The settling of gastrointestinal symptoms at 36–48 h is the classic point of wrongful discharge; the transaminases are already rising. A suspected amatoxin patient is not cleared by feeling better.¹
A serum amatoxin level is not a management number, and a urinary assay, where available, confirms exposure rather than guiding treatment — decisions rest on the history, the timing and the evolving liver function.¹
The prognostic markers come too late to guide toxin treatment. A falling prothrombin index / rising INR and a low Factor V predict the need for transplantation but appear days in — they are for the transplant decision, not the antidote decision.¹

The antidote, from the poison's side

There is no licensed specific antidote to amatoxin, and the honest framing is that amatoxin management is a race to intercept the toxin before uptake, not a reversal after it.¹ The agents used divide by where in the sequence they act.

Silibinin — a competitive uptake blocker, which is why timing is everything

Silibinin (the milk-thistle flavonolignan, given intravenously as Legalon SIL) is the specific agent, and its mechanism is precisely a mechanism this page has been building towards: it competes with amatoxin for the hepatocyte transmembrane transporters, so less toxin enters the cell, and it is thought also to interrupt the enterohepatic re-uptake that re-presents toxin to the liver.¹ Because it works at the uptake step, it can only protect hepatocytes the toxin has not yet entered — which is why it is recommended as early as possible and within about 48 hours of ingestion, and why a day's delay waiting for confirmation is so costly. It is a hepatoprotectant, not a toxin-neutraliser: it saves the cells that are still saveable. Established

N-acetylcysteine is used as an adjunct — an antioxidant and general hepatoprotectant rather than an amatoxin-specific agent, familiar from the paracetamol page and with a favourable safety profile that makes it easy to justify while the diagnosis is being clarified.¹ Benzylpenicillin (penicillin G) has long been given on the theory that it displaces amatoxin from plasma protein and reduces hepatic uptake, but amatoxin is barely protein-bound, the mechanistic basis is weak, and the largest retrospective analysis found penicillin among the least effective interventions — combining it with silibinin has not been shown superior to silibinin alone.¹² Activated charcoal, including repeated doses, targets the enterohepatic loop.¹

Critical appraisal

The RNA polymerase II mechanism and the resulting delayed hepatorenal injury are established. Amatoxin's inhibition of RNA polymerase II, and the consequent failure of protein synthesis in high-turnover cells, is well demonstrated and explains the organ selectivity and the latency.¹ Established
Silibinin's benefit is biologically compelling but not trial-proven. Its competitive-uptake mechanism is sound and it is the recommended specific agent, but the supporting clinical data are retrospective and observational; no randomised controlled trial has demonstrated a mortality benefit, and the honest position is mechanistic confidence with modest outcome evidence.¹ Inferred
Penicillin G is traditional teaching that the data do not support. It has been given for decades on a protein-displacement rationale that a barely-protein-bound toxin undermines, and the large retrospective analysis ranked it among the least effective measures; it persists more by habit than by evidence.¹² Traditional teaching
Extracorporeal removal has no documented outcome benefit. Amatoxin's low protein binding invites the idea, but its rapid plasma clearance and hepatic sequestration mean that by the time poisoning is recognised there is little in the plasma to remove, and the data do not show a benefit.¹
The prognostic thresholds are indicators, not rules. The prothrombin/INR and Factor V criteria for considering transplantation are drawn from retrospective series and specialist practice, and the transplant decision is a hepatology judgement rather than a number crossed.

References

1
Santi L, Maggioli C, Mastroroberto M, Tufoni M, Napoli L, Caraceni P. Acute liver failure caused by Amanita phalloides poisoning. International Journal of Hepatology 2012;2012:487480. PMID 22811920. PMC3395149.
2
Enjalbert F, Rapior S, Nouguier-Soulé J, Guillon S, Amouroux N, Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. Journal of Toxicology — Clinical Toxicology 2002;40(6):715–57. PMID 12475187.

Death cap and the amatoxin mushrooms

At a glance